{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:58:27Z","timestamp":1785578307439,"version":"3.56.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["Discovery\/IIRP\/SG-5195\/2023"],"award-info":[{"award-number":["Discovery\/IIRP\/SG-5195\/2023"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00203-026-04936-0","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:52:59Z","timestamp":1779695579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination strategies targeting multiple ETC subunits as a rational approach for drug-resistant TB therapy"],"prefix":"10.1007","volume":"208","author":[{"given":"Shashikanta","family":"Sau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja Kumari","family":"Agnivesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin Pal","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"February","key":"4936_CR1","first-page":"1","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler JAM, Maartens G, Meintjes G, Wasserman S (2023) Clofazimine for the treatment of tuberculosis. Front Pharmacol 14(February):1\u201318","journal-title":"Front Pharmacol"},{"issue":"6","key":"4936_CR2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jac\/38.6.1049","volume":"38","author":"L Amaral","year":"1996","unstructured":"Amaral L, Kristiansen JE, Abebe LS, Millett W (1996) Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 38(6):1049\u20131053","journal-title":"J Antimicrob Chemother"},{"key":"4936_CR3","doi-asserted-by":"crossref","unstructured":"Amaral L, Kristiansen JE, Viveiros M, Atouguia J (2001) RA solution to Antibiotic resistance in mycobacteria 505\u2013511","DOI":"10.1093\/jac\/47.5.505"},{"issue":"5707","key":"4936_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, G\u00f6hlmann HWH, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, De Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223\u2013227","journal-title":"Science"},{"issue":"7","key":"4936_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, De Jong BC, Koul A (2014) Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9(7):1\u201311","journal-title":"PLoS One"},{"issue":"9","key":"4936_CR6","first-page":"1","volume":"13","author":"F Appetecchia","year":"2020","unstructured":"Appetecchia F, Consalvi S, Scarpecci C, Biava M, Poce G (2020) Sar analysis of small molecules interfering with energy-metabolism in Mycobacterium tuberculosis. Pharmaceuticals Basel 13(9):1\u201333","journal-title":"Pharmaceuticals Basel"},{"key":"4936_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087329","author":"J Bacon","year":"2014","unstructured":"Bacon J, Alderwick LJ, Allnutt JA, Gabasova E, Watson R, Hatch KA, Clark SO, Jeeves RE, Marriott A, Rayner E, Tolley H, Pearson G, Hall G, Besra GS, Wernisch L, Williams A, Marsh PD (2014) Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0087329","journal-title":"PLoS One"},{"issue":"November","key":"4936_CR8","first-page":"1","volume":"10","author":"S Bajeli","year":"2020","unstructured":"Bajeli S, Baid N, Kaur M, Pawar GP, Chaudhari VD, Kumar A (2020) Terminal respiratory oxidases: a targetables vulnerability of mycobacterial bioenergetics? Front Cell Infect Microbiol 10(November):1\u201322","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"4936_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-22343-4","volume":"8","author":"JJ Baker","year":"2018","unstructured":"Baker JJ, Abramovitch RB (2018) Genetic and metabolic regulation of Mycobacterium tuberculosis acid growth arrest. Sci Rep 8(1):1\u201316","journal-title":"Sci Rep"},{"issue":"1","key":"4936_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6968.2010.01959.x","volume":"308","author":"D Bald","year":"2010","unstructured":"Bald D, Koul A (2010) Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol Lett 308(1):1\u20137","journal-title":"FEMS Microbiol Lett"},{"issue":"2","key":"4936_CR11","first-page":"1","volume":"8","author":"D Bald","year":"2017","unstructured":"Bald D, Villellas C, Lu P, Koul A (2017) crossm Mycobacterium tuberculosis, a New. Am Soc Microbiol 8(2):1\u201311","journal-title":"Am Soc Microbiol"},{"issue":"1","key":"4936_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12956-2","volume":"10","author":"T Beites","year":"2019","unstructured":"Beites T, O\u2019Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang HJ, Sutphen ML, Weiner DM, Dayao EK, Zimmerman M, Prideaux B, Desai PV, Masquelin T, Via LE, Dartois V, Boshoff HI, Barry CE, Ehrt S, Schnappinger D (2019) Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun 10(1):1\u201312","journal-title":"Nat Commun"},{"issue":"1","key":"4936_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0924-8579(00)00199-0","volume":"16","author":"MV Bettencourt","year":"2000","unstructured":"Bettencourt MV, Bosne-David S, Amaral L (2000) Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16(1):69\u201371","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"4936_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1365-2958.2002.02779.x","volume":"43","author":"JC Betts","year":"2002","unstructured":"Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43(3):717\u2013731","journal-title":"Mol Microbiol"},{"issue":"5","key":"4936_CR15","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1128\/AAC.02293-13","volume":"58","author":"PA Black","year":"2014","unstructured":"Black PA, Warren RM, Louw GE, Van Helden PD, Victor TC, Kana BD (2014) Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2491\u20132503","journal-title":"Antimicrob Agents Chemother"},{"key":"4936_CR16","unstructured":"Chesov E, Chesov D, Maurer FP, Andres S, Utpatel C, Barilar I, Donica A, Reimann M, Niemann S, Lange C, Crudu V, Heyckendorf J, Merker M(2026) Emergence of bedaquiline resistance in a high tuberculosis burden country [Epub ahead of print]"},{"issue":"6823","key":"4936_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/35059006","volume":"409","author":"ST Cole","year":"2001","unstructured":"Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honor\u00e9 N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG (2001) Massive gene decay in the leprosy bacillus. Nature 409(6823):1007\u20131011","journal-title":"Nature"},{"issue":"3","key":"4936_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016","volume":"5","author":"GM Cook","year":"2017","unstructured":"Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehrl E, Berney M (2017) Drug discovery & development: state-of-the-art and future directions on the topic of targets: OXPHOS as a target space for tuberculosis: success, caution, and future directions. Microbiol Spectr 5(3):3\u201311","journal-title":"Microbiol Spectr"},{"key":"4936_CR19","doi-asserted-by":"crossref","unstructured":"Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehrl E, Berney M(2026) Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. Microbiology Spectrum;5(3)","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016"},{"issue":"24","key":"4936_CR20","doi-asserted-by":"publisher","first-page":"16651","DOI":"10.1021\/acs.jmedchem.2c01493","volume":"65","author":"S Dam","year":"2022","unstructured":"Dam S, Tangara S, Hamela C, Hattabi T, Fa\u00efon L, Carre P, Antoine R, Herledan A, Leroux F, Piveteau C, Eveque M, Flipo M, Deprez B, Kremer L, Willand N, Villemagne B, Hartkoorn RC (2022) Tricyclic spirolactams kill mycobacteria in vitro and in vivo by inhibiting Type II NADH dehydrogenases. J Med Chem 65(24):16651\u201316664","journal-title":"J Med Chem"},{"issue":"11","key":"4936_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois VA, Rubin EJ (2022) Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol 20(11):685\u2013701","journal-title":"Nat Rev Microbiol"},{"key":"4936_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/645460","author":"DG Deavall","year":"2012","unstructured":"Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol. https:\/\/doi.org\/10.1155\/2012\/645460","journal-title":"J Toxicol"},{"issue":"4","key":"4936_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","volume":"5","author":"K Dheda","year":"2017","unstructured":"Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GKH, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM (2017) The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5(4):291\u2013360","journal-title":"Lancet Respir Med"},{"issue":"19","key":"4936_CR24","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1016\/j.bmc.2014.07.050","volume":"22","author":"EA Dunn","year":"2014","unstructured":"Dunn EA, Roxburgh M, Larsen L, Smith RAJ, McLellan AD, Heikal A, Murphy MP, Cook GM (2014) Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis. Bioorg Med Chem 22(19):5320\u20135328","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"4936_CR25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1128\/JCM.03043-15","volume":"54","author":"JJ Dunn","year":"2016","unstructured":"Dunn JJ, Starke JR, Revell PA (2016) Laboratory diagnosis of Mycobacterium tuberculosis infection and disease in children. J Clin Microbiol 54(6):1434\u20131441","journal-title":"J Clin Microbiol"},{"issue":"7424","key":"4936_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nature11541","volume":"491","author":"Y Feng","year":"2012","unstructured":"Feng Y, Li W, Li J, Wang J, Ge J, Xu D, Liu Y, Wu K, Zeng Q, Wu JW, Tian C, Zhou B, Yang M (2012) Structural insight into the type-II mitochondrial NADH dehydrogenases. Nature 491(7424):478\u2013482","journal-title":"Nature"},{"issue":"4","key":"4936_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/2040622315582325","volume":"6","author":"SK Field","year":"2015","unstructured":"Field SK (2015) Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 6(4):170\u2013184","journal-title":"Ther Adv Chronic Dis"},{"key":"4936_CR28","doi-asserted-by":"crossref","unstructured":"Foo CSY, Pethe K, Lupien A (2339 2020) Oxidative Phosphorylation\u2014an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Applied Sciences 2020. Page 10(7):2339","DOI":"10.3390\/app10072339"},{"key":"4936_CR29","unstructured":"Global tuberculosis report 2025. (2025)"},{"issue":"4","key":"4936_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4161\/viru.23987","volume":"4","author":"SS Grant","year":"2013","unstructured":"Grant SS, Hung DT (2013) Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence 4(4):273\u2013283","journal-title":"Virulence"},{"issue":"9","key":"4936_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1002251","volume":"7","author":"JE Griffin","year":"2011","unstructured":"Griffin JE, Gawronski JD, DeJesus MA, Ioerger TR, Akerley BJ, Sassetti CM (2011) High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7(9):1\u20139","journal-title":"PLoS Pathog"},{"key":"4936_CR32","doi-asserted-by":"crossref","unstructured":"Grigorov AS, Martini BA, Sorokin VV, Azhikina TL, Mulyukin AL, Salina EG (2025) Insights into Mycobacterium abscessus survival under prolonged potassium de fi ciency and starvation. ;(November):1\u201317","DOI":"10.3389\/fcimb.2025.1668407"},{"issue":"1","key":"4936_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3201\/eid2701.203766","volume":"27","author":"CA Haley","year":"2021","unstructured":"Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, Gomez ME, Peloquin C, Ashkin D, Goswami ND (2021) Novel 6-month treatment for drug-resistant tuberculosis, United States. Emerg Infect Dis 27(1):332\u2013334","journal-title":"Emerg Infect Dis"},{"issue":"13","key":"4936_CR34","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1002\/anie.201800260","volume":"57","author":"MB Harbut","year":"2018","unstructured":"Harbut MB, Yang B, Liu R, Yano T, Vilch\u00e8ze C, Cheng B, Lockner J, Guo H, Yu C, Franzblau SG, Petrassi HM, Jacobs WR, Rubin H, Chatterjee AK, Wang F (2018) Small molecules targeting Mycobacterium tuberculosis Type II NADH dehydrogenase exhibit antimycobacterial activity. Angewandte Chemie (International ed in English) 57(13):3478\u20133482","journal-title":"Angewandte Chemie (International ed in English)"},{"issue":"5","key":"4936_CR35","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn RC, Uplekar S, Cole ST (2014) Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2979\u20132981","journal-title":"Antimicrob Agents Chemother"},{"issue":"January","key":"4936_CR36","first-page":"1","volume":"10","author":"EJ Hasenoehrl","year":"2021","unstructured":"Hasenoehrl EJ, Wiggins TJ, Berney M (2021) Bioenergetic inhibitors: antibiotic efficacy and mechanisms of action in Mycobacterium tuberculosis. Front Cell Infect Microbiol 10(January):1\u201326","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"4936_CR37","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/jac\/dkw244","volume":"71","author":"A Heikal","year":"2016","unstructured":"Heikal A, Hards K, Cheung CY, Menorca A, Timmer MSM, Stocker BL, Cook GM (2016) Activation of type II NADH dehydrogenase by Quinolinequinones mediates antitubercular cell death. J Antimicrob Chemother 71(10):2840\u20132847","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4936_CR38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/mmi.12507","volume":"91","author":"A Heikal","year":"2014","unstructured":"Heikal A, Nakatani Y, Dunn E, Weimar MR, Day CL, Baker EN, Lott JS, Sazanov LA, Cook GM (2014) Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation. Mol Microbiol 91(5):950\u2013964","journal-title":"Mol Microbiol"},{"key":"4936_CR39","first-page":"255","volume":"10","author":"DT Hoagland","year":"2016","unstructured":"Hoagland DT, Liu J, Lee RB, Lee RE (2016) New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev 10:255\u201372","journal-title":"Adv Drug Deliv Rev"},{"key":"4936_CR40","doi-asserted-by":"crossref","unstructured":"Hu X, Wu Z, Lei J, Zhu Y, Gao J (2026)Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis [Epub ahead of print]","DOI":"10.1186\/s12879-025-11067-2"},{"key":"4936_CR41","doi-asserted-by":"crossref","unstructured":"Iqbal IK, Bajeli S, Akela AK, Kumar A(2026) Bioenergetics of mycobacterium: An emerging landscape for drug discovery. Pathogens;7(1)","DOI":"10.3390\/pathogens7010024"},{"issue":"4","key":"4936_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","volume":"2","author":"SM Irwin","year":"2016","unstructured":"Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ (2016) Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB\/FeJ mice. ACS Infect Dis 2(4):251\u2013267","journal-title":"ACS Infect Dis"},{"key":"4936_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02339","author":"K Jakkala","year":"2019","unstructured":"Jakkala K, Ajitkumar P (2019) Hypoxic non-replicating persistent Mycobacterium tuberculosis develops thickened outer layer that helps in restricting rifampicin entry. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2019.02339","journal-title":"Front Microbiol"},{"issue":"7","key":"4936_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02637-16","volume":"61","author":"J Jang","year":"2017","unstructured":"Jang J, Kim R, Woo M, Jeong J, Kim G, Delorme V (2017) crossm efflux attenuates the antibacterial. Antimicrob Agents Chemother 61(7):1\u20138","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4936_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-38064-7","volume":"9","author":"AB Jeon","year":"2019","unstructured":"Jeon AB, Ackart DF, Li W, Jackson M, Melander RJ, Melander C, Abramovitch RB, Chicco AJ, Basaraba RJ, Obreg\u00f3n-Henao A (2019) 2-Aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain. Sci Rep 9(1):1\u201313","journal-title":"Sci Rep"},{"issue":"28","key":"4936_CR46","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1073\/pnas.1706139114","volume":"114","author":"NP Kalia","year":"2017","unstructured":"Kalia NP, Hasenoehrl EJ, Rahman NBA, Koh VH, Ang MLT, Sajorda DR, Hards K, Gr\u00fcber G, Alonso S, Cook GM, Berney M, Pethe K (2017) Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proc Natl Acad Sci U S A 114(28):7426\u20137431","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4936_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112444","volume":"42","author":"NP Kalia","year":"2023","unstructured":"Kalia NP, Singh S, Hards K, Cheung CY, Sviriaeva E, Banaei-Esfahani A, Aebersold R, Berney M, Cook GM, Pethe K (2023) M. tuberculosis relies on trace oxygen to maintain energy homeostasis and survive in hypoxic environments. Cell Rep 42(5):112444","journal-title":"Cell Rep"},{"issue":"1","key":"4936_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02919-20","volume":"60","author":"K Kaniga","year":"2022","unstructured":"Kaniga K, Hasan R, Jou R, Chuchottaworn C, Metchock B (2022) Bedaquiline drug resistance emergence assessment in prospective in vitro surveillance study of Bedaquiline and other. J Clin Microbiol 60(1):e02919-20","journal-title":"J Clin Microbiol"},{"key":"4936_CR49","doi-asserted-by":"crossref","unstructured":"Khawbung JL, Nath D, Chakraborty S (2021) Drug resistant Tuberculosis: A review. Comp Immunol Microbiol Infect Dis ;74101574","DOI":"10.1016\/j.cimid.2020.101574"},{"key":"4936_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, Motahar M, Moradi M, Bazyar H (2021) Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist 25:48\u201359","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4936_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01123-22","volume":"67","author":"J Kim","year":"2023","unstructured":"Kim J, Choi J, Kang H, Ahn J, Hutchings J, van Niekerk C, Kim J, Jeon Y, Nam K, Kim TH, Shin BS, Shin S (2023) Safety, tolerability, pharmacokinetics, and metabolism of Telacebec (Q203) for the treatment of tuberculosis: a randomized, placebo-controlled, multiple ascending dose Phase 1B trial. Antimicrob Agents Chemother 67(1):e01123-22","journal-title":"Antimicrob Agents Chemother"},{"key":"4936_CR52","doi-asserted-by":"crossref","unstructured":"Koch A, Cox H, Mizrahi V (2018) Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol ;427\u2013415","DOI":"10.1016\/j.coph.2018.05.013"},{"issue":"1","key":"4936_CR53","doi-asserted-by":"publisher","first-page":"e00962","DOI":"10.1128\/aac.00962-24","volume":"69","author":"OD Komm","year":"2025","unstructured":"Komm OD, Tyagi S, Garcia A, Almeida D, Chang Y, Li S-Y, Castillo JR, Converse PJ, Black T, Fotouhi N, Nuermberger EL (2025) Contribution of Telacebec to novel drug regimens in a murine tuberculosis model. Antimicrob Agents Chemother 69(1):e00962\u2013e00924","journal-title":"Antimicrob Agents Chemother"},{"key":"4936_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4369","author":"A Koul","year":"2014","unstructured":"Koul A, Vranckx L, Dhar N, G\u00f6hlmann HWH, \u00d6zdemir E, Neefs JM, Schulz M, Lu P, M\u00f8rtz E, McKinney JD, Andries K, Bald D (2014) Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms4369","journal-title":"Nat Commun"},{"issue":"December","key":"4936_CR55","first-page":"1","volume":"13","author":"A Kumar","year":"2011","unstructured":"Kumar A, Farhana A, Guidry L, Saini V, Hondalus M, Steyn AJC (2011) Redox homeostasis in mycobacteria: the key to tuberculosis control? Expert Rev Mol Med 13(December):1\u201325","journal-title":"Expert Rev Mol Med"},{"issue":"April","key":"4936_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118323","volume":"129","author":"R Kumar","year":"2025","unstructured":"Kumar R, Roy A, Kalia NP, Sharma DK (2025) Inhibition of cytochrome bd oxidase in Mycobacterium tuberculosis by benzothiazole amides. Bioorg Med Chem 129(April):118323","journal-title":"Bioorg Med Chem"},{"issue":"March 2017","key":"4936_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tube.2017.10.008","volume":"108","author":"S Kumar","year":"2018","unstructured":"Kumar S, Mehra R, Sharma S, Bokolia NP, Raina D, Nargotra A, Singh PP, Khan IA (2018) Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis. Tuberculosis 108(March 2017):56\u201363","journal-title":"Tuberculosis"},{"key":"4936_CR58","doi-asserted-by":"crossref","unstructured":"Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, Adamson JH, Steyn AJC(2026) Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nature Communications;7","DOI":"10.1038\/ncomms12393"},{"issue":"1","key":"4936_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09031936.00188313","volume":"44","author":"C Lange","year":"2014","unstructured":"Lange C, Abubakar I, Alffenaar JWC, Bothamley G, Caminero JA, Carvalho ACC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, G\u00fcnther G, Ibraim E, Kampmann B, Kuksa L, De Lange W, Van Leth F, Van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, R\u00fcsch-Gerdes S, Sandgren A, Scardigli S, Skrahina A, Tortoli E, Volchenkov G, Wagner D, Van Der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM (2014) Management of patients with multidrugresistant\/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44(1):23\u201363","journal-title":"Eur Respir J"},{"issue":"10","key":"4936_CR60","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00063-25","volume":"93","author":"J Li","year":"2025","unstructured":"Li J, Wang Y, He L, Yang L, Tao T, Bai L, Luo Y (2025) Host-directed therapeutic targets in macrophages and their ligands against Mycobacterium tuberculosis. Infect Immun 93(10):e0006325","journal-title":"Infect Immun"},{"issue":"6","key":"4936_CR61","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.cclet.2020.04.007","volume":"31","author":"Q Li","year":"2020","unstructured":"Li Q, Lu X (2020) New antituberculosis drugs targeting the respiratory chain. Chin Chem Lett 31(6):1357\u20131365","journal-title":"Chin Chem Lett"},{"issue":"7","key":"4936_CR62","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1021\/acs.jmedchem.5c00049","volume":"68","author":"Y Liang","year":"2025","unstructured":"Liang Y, Bueler SA, Cook GM, Rubinstein JL (2025) Structure of mycobacterial NDH-2 bound to a 2-Mercapto-Quinazolinone inhibitor. J Med Chem 68(7):7579\u20137591","journal-title":"J Med Chem"},{"issue":"3","key":"4936_CR63","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1021\/acsinfecdis.1c00413","volume":"8","author":"L Lu","year":"2022","unstructured":"Lu L, \u00c5kerbladh L, Ahmad S, Konda V, Cao S, Vocat A, Maes L, Cole ST, Hughes D, Larhed M, Brandt P, Karl\u00e9n A, Mowbray SL (2022) Synthesis and in vitro biological evaluation of quinolinyl pyrimidines targeting type II NADH-dehydrogenase (NDH-2). ACS Infect Dis 8(3):482\u2013498","journal-title":"ACS Infect Dis"},{"key":"4936_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-18","author":"A Lupien","year":"2018","unstructured":"Lupien A, Vocat A, Foo CSY, Blattes E, Gillon JY, Makarov V, Cole ST (2018) Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169). Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00840-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4936_CR65","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1016\/j.bmcl.2007.03.064","volume":"17","author":"PB Madrid","year":"2007","unstructured":"Madrid PB, Polgar WE, Toll L, Tanga MJ (2007) Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg Med Chem Lett 17(11):3014\u20133017","journal-title":"Bioorg Med Chem Lett"},{"key":"4936_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac029","author":"JS Mallick","year":"2022","unstructured":"Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T (2022) Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob Resist. https:\/\/doi.org\/10.1093\/jacamr\/dlac029","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"4936_CR67","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3201\/eid2005.131037","volume":"20","author":"SM Marks","year":"2014","unstructured":"Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K (2014) Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005\u20132007. Emerg Infect Dis 20(5):812\u2013821","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"4936_CR68","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1473-3099(25)00218-X","volume":"25","author":"L Mdlenyani","year":"2021","unstructured":"Mdlenyani L, Mohamed Z, Stadler JAM, Mtwa N, Meintjes G, Warren R, Saunders MJ, Kuhlin J, Wasserman S (2021) Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study. Lancet Infect Dis 25(10):1149\u20131158","journal-title":"Lancet Infect Dis"},{"issue":"12 December","key":"4936_CR69","first-page":"1","volume":"16","author":"P Mishra","year":"2021","unstructured":"Mishra P, Sharma RK, Yadav R, Rao VG, Nigam S, Lingala MA, Bhat J (2021) Reasons for loss to follow-up (LTFU) of pulmonary TB (PTB) patients: a qualitative study among Saharia, a particularly vulnerable tribal group of Madhya Pradesh, India. PLoS One 16(12 December):1\u201315","journal-title":"PLoS One"},{"issue":"2","key":"4936_CR70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1574-6968.2008.01451.x","volume":"291","author":"T Mogi","year":"2009","unstructured":"Mogi T, Matsushita K, Murase Y, Kawahara K, Miyoshi H, Ui H, Shiomi K, Omura S, Kita K (2009) Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II): Research letter. FEMS Microbiol Lett 291(2):157\u2013161","journal-title":"FEMS Microbiol Lett"},{"issue":"10","key":"4936_CR71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cmi.2019.06.014","volume":"25","author":"I Mokrousov","year":"2019","unstructured":"Mokrousov I, Akhmedova G, Polev D, Molchanov V, Vyazovaya A (2019) Acquisition of bedaquiline resistance by extensively drug-resistant Mycobacterium tuberculosis strain of Central Asian outbreak clade. Clin Microbiol Infect 25(10):1295\u20131297","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"4936_CR72","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","volume":"4","author":"D Murugesan","year":"2018","unstructured":"Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, Soares De Melo C, Feng TS, Street LJ, Chibale K, Warner DF, Mizrahi V, Epemolu O, Scullion P, Ellis L, Riley J, Shishikura Y, Ferguson L, Osuna-Cabello M, Read KD, Green SR, Lamprecht DA, Steyn AJC, Ioerger TR, Sacchettini J, Rhee KY, Arora K, Barry CE, Wyatt PG, Boshoff HIM (2018) 2-Mercapto-Quinazolinones as inhibitors of type II NADH dehydrogenase and Mycobacterium tuberculosis: structure-activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization. ACS Infect Dis 4(6):954\u2013969","journal-title":"ACS Infect Dis"},{"key":"4936_CR73","unstructured":"Nagdev PK, Agnivesh PK, Roy A, Sau S, Kalia NP (2026) Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection. Eur J Clin Microbiol Infect Dis (0123456789): [Epub ahead of print]."},{"issue":"5","key":"4936_CR74","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11306-025-02320-5","volume":"21","author":"TJ Naidoo","year":"2025","unstructured":"Naidoo TJ, Ashokcoomar S, Truebody B, Mackenzie JS, Steyn AJC, Pillay M (2025) Mycobacterium tuberculosis curli pili facilitates pathogenicity by modulating central carbon metabolism. Metabolomics 21(5):118","journal-title":"Metabolomics"},{"issue":"3","key":"4936_CR75","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1021\/jacs.9b10254","volume":"142","author":"Y Nakatani","year":"2020","unstructured":"Nakatani Y, Shimaki Y, Dutta D, Muench SP, Ireton K, Cook GM, Jeuken LJC (2020) Unprecedented properties of phenothiazines unraveled by a NDH-2 bioelectrochemical assay platform. J Am Chem Soc 142(3):1311\u20131320","journal-title":"J Am Chem Soc"},{"issue":"1","key":"4936_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12864-017-3911-3","volume":"18","author":"A Namouchi","year":"2017","unstructured":"Namouchi A, Cimino M, Favre-Rochex S, Charles P, Gicquel B (2017) Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery. BMC Genomics 18(1):25\u201328","journal-title":"BMC Genomics"},{"issue":"6","key":"4936_CR77","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5588\/ijtld.21.0035","volume":"25","author":"S Oelofse","year":"2021","unstructured":"Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Wills GH, Olugbosi M, del Parigi A, Sun E, Calatroni A, Spigelman M, Dheda K (2021) Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts. Int J Tuberc Lung Dis 25(6):453\u2013460","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"4936_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/jac\/dkad372","volume":"79","author":"S Omar","year":"2024","unstructured":"Omar S, Whitfield MG, Nolan MB, Ngom JT, Ismail N, Warren RM, Klopper M (2024) Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis. J Antimicrob Chemother 79(2):211\u2013240","journal-title":"J Antimicrob Chemother"},{"key":"4936_CR79","unstructured":"Ommi O, Paoletti N, Bonardi A, Gratteri P, Bhalerao HA, Sau S, Nanduri S, Mohammed A, Kalia NP, Sonti R, Supuran CT, Yaddanapudi VM (2026) Exploration of 3-aryl pyrazole-tethered sulfamoyl carboxamides as carbonic anhydrase inhibitors. Archiv der Pharmazie;(June): [Epub ahead of print]"},{"issue":"3","key":"4936_CR80","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","volume":"47","author":"D Ordway","year":"2003","unstructured":"Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L (2003) Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47(3):917\u2013922","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4936_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjgh-2018-001097","volume":"4","author":"N Padayatchi","year":"2019","unstructured":"Padayatchi N, Daftary A, Naidu N, Naidoo K, Pai M (2019) Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa. BMJ Glob Health 4(1):1\u20136","journal-title":"BMJ Glob Health"},{"issue":"4","key":"4936_CR82","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1039\/D4MD00829D","volume":"16","author":"S Perveen","year":"2025","unstructured":"Perveen S, Pal S, Sharma R (2025) Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target. RSC Med Chem 16(4):1476\u20131498","journal-title":"RSC Med Chem"},{"issue":"9","key":"4936_CR83","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SPS, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19(9):1157\u20131160","journal-title":"Nat Med"},{"key":"4936_CR84","doi-asserted-by":"crossref","unstructured":"Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SPS, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nature Medicine. 19:9 2013;19(9):1157\u20131160","DOI":"10.1038\/nm.3262"},{"issue":"0","key":"4936_CR85","first-page":"e02282","volume":"0","author":"R Priya","year":"2023","unstructured":"Priya R, Pearly SN, Samsher S, Han PW, Dennis L, Pal KN, Simon L, Amaravadhi H, RS A, Volker WIP, Garrett M, Thomas MJMM, Kevin D, Gerhard P (2023) GaMF1.39\u2019s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876. Microbiol Spectr 0(0):e02282\u2013e02223","journal-title":"Microbiol Spectr"},{"issue":"33","key":"4936_CR86","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SPS Rao","year":"2008","unstructured":"Rao SPS, Alonso S, Rand L, Dick T, Pethe K (2008) The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 105(33):11945\u201311950","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4936_CR87","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.sjbs.2017.01.004","volume":"24","author":"IA Rather","year":"2017","unstructured":"Rather IA, Kim BC, Bajpai VK, Park YH (2017) Self-medication and antibiotic resistance: crisis, current challenges, and prevention. Saudi J Biol Sci 24(4):808\u2013812","journal-title":"Saudi J Biol Sci"},{"issue":"9","key":"4936_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103693","volume":"28","author":"A Roy","year":"2023","unstructured":"Roy A, Kumari Agnivesh P, Sau S, Kumar S, Pal Kalia N (2023) Tweaking host immune responses for novel therapeutic approaches against Mycobacterium tuberculosis. Drug Discov Today 28(9):103693","journal-title":"Drug Discov Today"},{"issue":"2","key":"4936_CR89","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/acsinfecdis.4c01005","volume":"11","author":"P Saha","year":"2025","unstructured":"Saha P, Kumar M, Sharma DK (2025) Potential of Mycobacterium tuberculosis type II NADH-dehydrogenase in antitubercular drug discovery. ACS Infect Dis 11(2):398\u2013412","journal-title":"ACS Infect Dis"},{"issue":"10","key":"4936_CR90","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1021\/acsinfecdis.4c00710","volume":"10","author":"P Saha","year":"2024","unstructured":"Saha P, Sau S, Kalia NP, Sharma DK (2024) 2-Aryl-benzoimidazoles as Type II NADH dehydrogenase inhibitors of Mycobacterium tuberculosis. ACS Infect Dis 10(10):3699\u20133711","journal-title":"ACS Infect Dis"},{"issue":"5","key":"4936_CR91","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1039\/D4MD00118D","volume":"15","author":"P Saha","year":"2024","unstructured":"Saha P, Sau S, Kalia NP, Sharma DK (2024) Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase. RSC Med Chem 15(5):1664\u20131674","journal-title":"RSC Med Chem"},{"issue":"July","key":"4936_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108718","volume":"163","author":"P Saha","year":"2025","unstructured":"Saha P, Sau S, Pal N, Sharma DK (2025) Bioorganic chemistry targeting drug-resistant tuberculosis: thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenase. Bioorg Chem 163(July):108718","journal-title":"Bioorg Chem"},{"key":"4936_CR93","unstructured":"Saha P, sau shashikanta, Kalia NP, Sharma DK(2026) Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase. RSC Medicinal Chemistry;1825"},{"issue":"16","key":"4936_CR94","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1016\/j.bmc.2019.06.002","volume":"27","author":"KT Santoso","year":"2019","unstructured":"Santoso KT, Menorca A, Cheung CY, Cook GM, Stocker BL, Timmer MSM (2019) The synthesis and evaluation of Quinolinequinones as anti-mycobacterial agents. Bioorg Med Chem 27(16):3532\u20133545","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"4936_CR95","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","volume":"48","author":"CM Sassetti","year":"2003","unstructured":"Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48(1):77\u201384","journal-title":"Mol Microbiol"},{"key":"4936_CR96","doi-asserted-by":"crossref","unstructured":"Sau S, Kalia NP (2026)Perspectives on Anti-Tuberculosis Drug Discovery BT - Drugs and a Methodological Compendium: From bench to bedside. In: Rajput VS, Runthala A (eds) Singapore: Springer Nature Singapore; p 357\u2013375","DOI":"10.1007\/978-981-19-7952-1_13"},{"issue":"1","key":"4936_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-53107-3","volume":"9","author":"WG Saw","year":"2019","unstructured":"Saw WG, Wu ML, Ragunathan P, Biukovi\u0107 G, Lau AM, Shin J, Harikishore A, Cheung CY, Hards K, Sarathy JP, Bates RW, Cook GM, Dick T, Gr\u00fcber G (2019) Disrupting coupling within mycobacterial F-ATP synthases subunit \u03b5 causes dysregulated energy production and cell wall biosynthesis. Sci Rep 9(1):1\u201315","journal-title":"Sci Rep"},{"issue":"6","key":"4936_CR98","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/adt.2016.717","volume":"14","author":"K Schaaf","year":"2016","unstructured":"Schaaf K, Hayley V, Speer A, Wolschendorf F, Niederweis M, Kutsch O, Sun J (2016) A macrophage infection model to predict drug efficacy against Mycobacterium tuberculosis. Assay Drug Dev Technol 14(6):345\u2013354","journal-title":"Assay Drug Dev Technol"},{"issue":"5","key":"4936_CR99","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1084\/jem.20030846","volume":"198","author":"D Schnappinger","year":"2003","unstructured":"Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, Schoolnik GK (2003) Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198(5):693\u2013704","journal-title":"J Exp Med"},{"issue":"1","key":"4936_CR100","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.chom.2015.06.001","volume":"18","author":"OT Schubert","year":"2015","unstructured":"Schubert OT, Ludwig C, Kogadeeva M, Zimmermann M, Rosenberger G, Gengenbacher M, Gillet LC, Collins BC, Rost HL, Kaufmann SHE, Sauer U, Aebersold R (2015) Absolute proteome composition and dynamics during dormancy and resuscitation of Mycobacterium tuberculosis. Cell Host Microbe 18(1):96\u2013108","journal-title":"Cell Host Microbe"},{"issue":"6","key":"4936_CR101","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14728222.2017.1327577","volume":"21","author":"S Sellamuthu","year":"2017","unstructured":"Sellamuthu S, Singh M, Kumar A, Singh SK (2017) Type-II NADH dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery. Expert Opin Ther Targets 21(6):559\u2013570","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"4936_CR102","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/mmi.13120","volume":"98","author":"FV Sena","year":"2015","unstructured":"Sena FV, Batista AP, Catarino T, Brito JA, Archer M, Viertler M, Madl T, Cabrita EJ, Pereira MM (2015) Type-II NADH: quinone oxidoreductase from Staphylococcus aureus has two distinct binding sites and is rate limited by quinone reduction. Mol Microbiol 98(2):272\u2013288","journal-title":"Mol Microbiol"},{"issue":"2","key":"4936_CR103","first-page":"1","volume":"11","author":"DP Shan Chang","year":"2021","unstructured":"Shan Chang DP, Guan XL (2021) Metabolic versatility of Mycobacterium tuberculosis during infection and dormancy. Metabolites 11(2):1\u201321","journal-title":"Metabolites"},{"issue":"4","key":"4936_CR104","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00340-23","volume":"14","author":"R Sharma","year":"2023","unstructured":"Sharma R, Hartman TE, Beites T, Kim J-H, Eoh H, Engelhart CA, Zhu L, Wilson DJ, Aldrich CC, Ehrt S, Rhee KY, Schnappinger D (2023) Metabolically distinct roles of NAD synthetase and NAD kinase define the essentiality of NAD and NADP in Mycobacterium tuberculosis. mBio 14(4):e00340-23","journal-title":"mBio"},{"key":"4936_CR105","doi-asserted-by":"crossref","unstructured":"Shetye GS, Franzblau SG, Cho S (2020) New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Translational Res ;22068\u201322097","DOI":"10.1016\/j.trsl.2020.03.007"},{"issue":"9","key":"4936_CR106","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1021\/ml300134b","volume":"3","author":"PS Shirude","year":"2012","unstructured":"Shirude PS, Paul B, Roy Choudhury N, Kedari C, Bandodkar B, Ugarkar BG (2012) Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med Chem Lett 3(9):736\u2013740","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"4936_CR107","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2174\/187152607781001781","volume":"7","author":"JS Teh","year":"2008","unstructured":"Teh JS, Yano T, Rubin H (2008) Type II NADH:menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect Disord Drug Targets 7(2):169\u2013181","journal-title":"Infect Disord Drug Targets"},{"key":"4936_CR108","doi-asserted-by":"crossref","unstructured":"Thomas SS, Kalia NP, Ruf MT, Pluschke G, Pethe K (2026) Toward a single-dose cure for buruli ulcer. Antimicrob Agents Chemother ;64(9)","DOI":"10.1128\/AAC.00727-20"},{"key":"4936_CR109","doi-asserted-by":"crossref","unstructured":"Tizzano B, Dallenga TK, Utpatel C, Behrends J, Homolka S, Kohl TA, Niemann S (2021) Survival of hypoxia-induced dormancy is not a common feature of all strains of the Mycobacterium tuberculosis complex. Scientific Reports. 11:1 2021;11(1):1\u201313","DOI":"10.1038\/s41598-021-81223-6"},{"issue":"4","key":"4936_CR110","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1128\/9781555818845.ch22","volume":"2","author":"C Vilch\u00e8ze","year":"2015","unstructured":"Vilch\u00e8ze C, Jacobs WR (2015) Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Mol Genet Mycobact 2(4):431\u2013453","journal-title":"Mol Genet Mycobact"},{"issue":"7","key":"4936_CR111","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1073\/pnas.1721545115","volume":"115","author":"C Vilch\u00e8ze","year":"2018","unstructured":"Vilch\u00e8ze C, Weinrick B, Leung LW, Jacobs WR (2018) Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence. Proc Natl Acad Sci U S A 115(7):1599\u20131604","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4936_CR112","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1128\/AAC.49.2.708-720.2005","volume":"49","author":"C Vilch\u00e8ze","year":"2005","unstructured":"Vilch\u00e8ze C, Weisbrod TR, Chen B, Kremer L, Hazb\u00f3n MH, Wang F, Alland D, Sacchettini JC, Jacobs WR (2005) Altered NADH\/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49(2):708\u2013720","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4936_CR113","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dks483","volume":"68","author":"AJ Warman","year":"2013","unstructured":"Warman AJ, Rito TS, Fisher NE, Moss DM, Berry NG, O\u2019Neill PM, Ward SA, Biagini GA (2013) Antitubercular pharmacodynamics of phenothiazines. J Antimicrob Chemother 68(4):869\u2013880","journal-title":"J Antimicrob Chemother"},{"issue":"June","key":"4936_CR114","first-page":"1","volume":"12","author":"K Wasik","year":"2022","unstructured":"Wasik K, Lechowicz E, Antczak M, Rumijowska-galewicz A (2022) The orphan response regulator Rv3143 modulates the activity of the NADH dehydrogenase complex ( Nuo ) in Mycobacterium tuberculosis via protein \u2013 protein interactions. Front Cell Infect Microbiol 12(June):1\u201318","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"4936_CR115","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/iai.64.6.2062-2069.1996","volume":"64","author":"LG Wayne","year":"1996","unstructured":"Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64(6):2062\u20132069","journal-title":"Infect Immun"},{"key":"4936_CR116","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.micro.55.1.139","volume":"55","author":"LG Wayne","year":"2001","unstructured":"Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139\u2013163","journal-title":"Annu Rev Microbiol"},{"issue":"12","key":"4936_CR117","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.0500469102","volume":"102","author":"EA Weinstein","year":"2005","unstructured":"Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H (2005) Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci U S A 102(12):4548\u20134553","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4936_CR118","doi-asserted-by":"crossref","unstructured":"Wilburn KM, Fieweger RA, VanderVen BC(2026) Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis. Pathogens disease ;76(2)","DOI":"10.1093\/femspd\/fty021"},{"key":"4936_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143541","author":"H Wu","year":"2025","unstructured":"Wu H, Huang M-Y, Xue Z-J, Zhong S-Y, Shi J-Q, Chen N-P, Qian C-D (2025) Targeting type II NADH dehydrogenase in tuberculosis treatment: a review. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143541","journal-title":"Int J Biol Macromol"},{"key":"4936_CR120","unstructured":"Xu Y, Ehrt S, Schnappinger D,(2026) Beites T Synthetic lethality of Mycobacterium tuberculosis NADH dehydrogenases is due to impaired NADH oxidation. bioRxiv: the preprint server for biology"},{"issue":"2","key":"4936_CR121","first-page":"1","volume":"42","author":"Y Xu","year":"2022","unstructured":"Xu Y, Pooja, Borah K (2022) Mycobacterium tuberculosis carbon and nitrogen metabolic fluxes. Biosci Rep 42(2):1\u201311","journal-title":"Biosci Rep"},{"issue":"12","key":"4936_CR122","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano T, Kassovska-Bratinova S, Shin Teh J, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H (2011) Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286(12):10276\u201310287","journal-title":"J Biol Chem"},{"issue":"17","key":"4936_CR123","doi-asserted-by":"publisher","first-page":"11456","DOI":"10.1074\/jbc.M508844200","volume":"281","author":"T Yano","year":"2006","unstructured":"Yano T, Lin-Sheng L, Weinstein E, Teh JS, Rubin H (2006) Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis Type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 281(17):11456\u201311463","journal-title":"J Biol Chem"},{"issue":"7","key":"4936_CR124","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1021\/bi4013897","volume":"53","author":"T Yano","year":"2014","unstructured":"Yano T, Rahimian M, Aneja KK, Schechter NM, Rubin H, Scott CP (2014) Mycobacterium tuberculosis type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites. Biochemistry 53(7):1179\u20131190","journal-title":"Biochemistry"},{"issue":"4","key":"4936_CR125","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.3390\/molecules19044380","volume":"19","author":"D Zhang","year":"2014","unstructured":"Zhang D, Liu Y, Zhang C, Zhang H, Wang B, Xu J, Fu L, Yin D, Cooper CB, Ma Z, Lu Y, Huang H (2014) Synthesis and biological evaluation of novel 2-methoxypyridylamino- substituted riminophenazine derivatives as antituberculosis agents. Molecules 19(4):4380\u20134394","journal-title":"Molecules"},{"issue":"1","key":"4936_CR126","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12864-025-11653-3","volume":"26","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Hou Y, Yin H, Lu S, Liu D, Cheng L, Yu H, Li T, Zhao Y (2025) Comparative transcriptomic and proteomic analyses of hypoxia response in wild and cultivated tomato roots. BMC Genomics 26(1):552","journal-title":"BMC Genomics"},{"key":"4936_CR127","unstructured":"Zhou J, Chen H, Xu J, Huang M, Wang J, Shen H, Shen S(2026) Myricetin Acts as an Inhibitor of Type II NADH Dehydrogenase from Staphylococcus aureus [Epub ahead of print]"},{"key":"4936_CR128","doi-asserted-by":"crossref","unstructured":"Zhu H, Zhou X, Zhuang Z, Li L, Bi J, Mi K(2026) Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children. Front Cell Infect Microbiol ;13(June)","DOI":"10.3389\/fcimb.2023.1183597"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-026-04936-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:02:23Z","timestamp":1785574943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-026-04936-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":128,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4936"],"URL":"https:\/\/doi.org\/10.1007\/s00203-026-04936-0","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is a review article that doesn\u2019t require prior approval.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"410"}}